Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.67 |
| ▸ | CNR2 | P34972 | 17/20 | 0.66 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30641079 | 1.00 | CNR1 (0.67) | CNR1CNR2HTR3A | |
| SCHEMBL30258887 | 0.99 | CNR1 (0.65) | CNR1CNR2HTR3A | |
| SCHEMBL31052992 | 0.99 | CNR1 (0.65) | CNR1CNR2HTR3A | |
| SCHEMBL29809369 | 0.92 | CNR1 (0.65) | CNR1CNR2HTR3A | |
| SCHEMBL24222020 | 0.91 | CNR1 (0.65) | CNR1CNR2HTR3A | |
| SCHEMBL30353000 | 0.89 | CNR1 (0.80) | CNR1CNR2HTR3A | |
| SCHEMBL25366701 | 0.89 | CNR1 (0.80) | CNR1CNR2HTR3A | |
| SCHEMBL31462484 | 0.89 | CNR1 (0.67) | CNR1CNR2HTR3A | |
| SCHEMBL4049645 | 0.87 | CNR1 (0.62) | CNR1CNR2HTR3A | |
| SCHEMBL29871232 | 0.87 | CNR1 (0.80) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| CN-115963258-B | Detection method and detection kit for synthetic cannabinoid | 上海八通生物科技股份有限公司 | 2025-01-17 | — | — | CN | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-115963258-A | Detection method and detection kit for synthetic cannabinoid | 上海八通生物科技股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-113267589-B | Analysis method of 16 synthetic cannabinoids and metabolites thereof in hair | 司法鉴定科学研究院 | 2022-11-04 | — | — | CN | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4646477-A2 | METHODS AND COMPOSITIONS FOR DISPLAYING PEPTIDE LIBRARIES | Board of Regents, The University of Texas System (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4639145-A1 | SYNTHETIC CANNABINOID DETECTION | The University of Bath (GB) | 2025-10-29 | — | — | EP | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250241933-A1 | METHODS OF TREATING SLEEP APNEA WITH A COMBINATION OF A CANNABINOID AND A CARBONIC ANHYDRASE INHIBITOR | APNIMED, INC. (DELAWARE) | 2025-07-31 | — | — | US | disclosed |
| US-20250216329-A1 | DRUG DETECTION | THE UNIVERSITY OF BATH (GB) | 2025-07-03 | — | — | US | disclosed |
| WO-2025137725-A2 | A METHOD OF CULTIVATING, PREPARING, AND USING A MATRIX-BLANK BIOMASS | PAULI CHRISTOPHER STEPHEN (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2023102541-A1 | METHODS AND COMPOSITIONS RELATED TO ENGINEERED CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-08 | — | — | WO | disclosed |
| CN-115963258-A | Detection method and detection kit for synthetic cannabinoid | 上海八通生物科技股份有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-11612581-B2 | Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects | CANNIBITE BVBA | 2023-03-28 | — | — | US | disclosed |
| CN-115728280-A | On-site detection method of synthetic cannabinoid JWH-018 | 中国科学院新疆理化技术研究所 | 2023-03-03 | — | — | CN | disclosed |
| US-20220406587-A1 | MASS SPECTROMETRY METHODS AND RELATED MATERIALS | THE TRUSTEES OF INDIANA UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| CN-113267589-B | Analysis method of 16 synthetic cannabinoids and metabolites thereof in hair | 司法鉴定科学研究院 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022221613-A1 | COMBINATION OF A NOREPINEPHRINE REUPTAKE INHIBITOR AND A CANNABINOID FOR USE IN TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) (US) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR1 221/4885CNR2 204/4885HTR3A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.